Statin Labeling Changes Include Class Warning About Glucose Effects

All statin labels now warn that “increases in HbA1C and fasting serum glucose levels have been reported” with the cholesterol-lowering drugs. Labels also reflect a relaxation of hepatic monitoring requirements, which could remove one hurdle to Pfizer’s pursuit of an OTC switch for Lipitor.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from United States

More from North America